Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. This study demonstrates that the trifunctional bsAb BiLu is able to kill tumor cells very efficiently without any additional costimulation of effector cells in vitro and in vivo. Remarkably, this bsAb also induces a long-lasting protective immunity against the targeted syngeneic mouse tumors (B16 melanoma and A20 B-cell lymphoma, respectively). A strong correlation was observed between the induction of a humoral immune response with tumor-reactive antibodies and the survival of mice. This humoral response was at least in part tumor specif...
In clinical trials a low affinity monclonal antibody (17.1A) to Ep-CAM, a tumour associated antigen ...
Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new adv...
BACKGROUND: Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules r...
A major goal of tumor immunotherapy is the induction of long-lasting systemic T-cell immunity. Bispe...
Numerous in vitro studies have shown that T lymphocytes can be targeted towards any target cell by u...
Immunotherapy is a powerful anti-cancer treatment modality. However, despite numerous encouraging re...
The incidence of lymphoma is rising, now representing 3% of cancers in the UK alone. Current treatme...
Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated t...
Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to r...
As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody the...
The specificity and efficiency of tumor-cell lysis by the retargeting of murine cytolytic lymphocyte...
To overcome dose limiting toxicities and to increase efficacy of immunotherapy of cancer, a number o...
A major goal of tumor immunotherapy is the induction of a systemic immune response against tumor ant...
The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement o...
Bi- and multispecific antibody derivatives (bsAbs) can be considered as the next generation of targe...
In clinical trials a low affinity monclonal antibody (17.1A) to Ep-CAM, a tumour associated antigen ...
Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new adv...
BACKGROUND: Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules r...
A major goal of tumor immunotherapy is the induction of long-lasting systemic T-cell immunity. Bispe...
Numerous in vitro studies have shown that T lymphocytes can be targeted towards any target cell by u...
Immunotherapy is a powerful anti-cancer treatment modality. However, despite numerous encouraging re...
The incidence of lymphoma is rising, now representing 3% of cancers in the UK alone. Current treatme...
Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated t...
Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to r...
As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody the...
The specificity and efficiency of tumor-cell lysis by the retargeting of murine cytolytic lymphocyte...
To overcome dose limiting toxicities and to increase efficacy of immunotherapy of cancer, a number o...
A major goal of tumor immunotherapy is the induction of a systemic immune response against tumor ant...
The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement o...
Bi- and multispecific antibody derivatives (bsAbs) can be considered as the next generation of targe...
In clinical trials a low affinity monclonal antibody (17.1A) to Ep-CAM, a tumour associated antigen ...
Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new adv...
BACKGROUND: Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules r...